<DOC>
	<DOCNO>NCT00120900</DOCNO>
	<brief_summary>This study design evaluate effectiveness GW406381 ( COX-2 inhibitor ) treat sign symptom osteoarthritis knee .</brief_summary>
	<brief_title>Evaluation GW406381 Treating Adults With Osteoarthritis Of The Knee</brief_title>
	<detailed_description>A Phase III , 12-week , Multicentre , Double-blind , Double-dummy , Randomised , Placebo- Active Comparator-Controlled , Parallel Group study investigate Efficacy Safety GW406381 1mg , 5mg , 10mg , 25mg 50mg administer orally daily , adult Osteoarthritis knee ( CXA30007 ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion criterion : Subjects primary diagnosis osteoarthritis knee symptom duration least 3 month . Use pain medication , COX2 inhibitor NSAID ( nonsteroidal antiinflammatory drug ) least 5 day per week . Exclusion criterion : History hypersensitivity intolerance pain medication . History gastroduodenal perforation and/or obstruction . History upper GI ( gastrointestinal ) ulceration within previous 6 month . History upper low GI bleed within previous year . History inflammatory bowel disease . Currently take sucralfate misoprostol . Currently take aspirin daily heart . Other restriction around use medication apply would need discuss . History coronary artery disease , ( angina , MI ) surgery . History congestive heart failure renal artery stenosis . History stroke transient ischemic attack . History uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>COX-2 inhibitor</keyword>
	<keyword>Knee osteoarthritis</keyword>
</DOC>